Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of rhTNF-NC plus toripalimab in advanced solid tumors after multiple prior treatment failures
ChiCTR2100041953Phase 2Recruiting
- Sponsor
- Heilongjiang Provincial Hospital
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rmhTNF-NC and toripalimab in Nonhematologic neoplasms, breast cancer, ovarian cancer and 2 more, sponsored by Heilongjiang Provincial Hospital. Primary endpoint: Objective response rate. Started Dec 2020; status: recruiting.
02
Drugs
rmhTNF-NCtoripalimab
03
Conditions
Nonhematologic neoplasmsbreast cancerovarian cancerprostate cancer (PCa)Bone and soft tissue sarcoma
Beyond the preview
Go deeper on ChiCTR2100041953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041953.